PL3173071T5 - Formulacja maropitantu - Google Patents

Formulacja maropitantu

Info

Publication number
PL3173071T5
PL3173071T5 PL16200848.6T PL16200848T PL3173071T5 PL 3173071 T5 PL3173071 T5 PL 3173071T5 PL 16200848 T PL16200848 T PL 16200848T PL 3173071 T5 PL3173071 T5 PL 3173071T5
Authority
PL
Poland
Prior art keywords
maropitant
formulation
maropitant formulation
Prior art date
Application number
PL16200848.6T
Other languages
English (en)
Other versions
PL3173071T3 (pl
Inventor
Marinus Maria Martinus Boeren
Rudolf Johannes Paridaans
Original Assignee
Le Vet B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57460319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3173071(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Le Vet B.V. filed Critical Le Vet B.V.
Publication of PL3173071T3 publication Critical patent/PL3173071T3/pl
Publication of PL3173071T5 publication Critical patent/PL3173071T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16200848.6T 2015-11-27 2016-11-28 Formulacja maropitantu PL3173071T5 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2015865A NL2015865B1 (en) 2015-11-27 2015-11-27 Maropitant Formulation.
EP16200848.6A EP3173071B2 (en) 2015-11-27 2016-11-28 Maropitant formulation

Publications (2)

Publication Number Publication Date
PL3173071T3 PL3173071T3 (pl) 2021-08-16
PL3173071T5 true PL3173071T5 (pl) 2026-02-09

Family

ID=57460319

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16200848.6T PL3173071T5 (pl) 2015-11-27 2016-11-28 Formulacja maropitantu

Country Status (13)

Country Link
EP (1) EP3173071B2 (pl)
CY (1) CY1124893T1 (pl)
DK (1) DK3173071T3 (pl)
ES (1) ES2873376T3 (pl)
FI (1) FI3173071T4 (pl)
HR (1) HRP20210986T1 (pl)
HU (1) HUE054584T2 (pl)
LT (1) LT3173071T (pl)
NL (1) NL2015865B1 (pl)
PL (1) PL3173071T5 (pl)
PT (1) PT3173071T (pl)
RS (1) RS62057B1 (pl)
SI (1) SI3173071T1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法
CA3207185A1 (en) * 2021-02-05 2022-08-11 Billal Tir High loading oral film formulation
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6340166A (ja) 1986-08-06 1988-02-20 Fuji Xerox Co Ltd 電子写真感光体
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
CA2554346C (en) 2004-01-30 2009-11-17 Pfizer Products Inc. Parenteral formulations comprising a beta-cyclodextrin and a preservative
US20080193997A1 (en) 2004-08-24 2008-08-14 Kenji Kangawa Liquid Preparation of Physiologically Active Peptide
BR112014012985B1 (pt) 2011-11-29 2020-05-12 Jurox Pty Ltd Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物

Also Published As

Publication number Publication date
NL2015865B1 (en) 2017-06-13
EP3173071B1 (en) 2021-03-24
HUE054584T2 (hu) 2021-09-28
PT3173071T (pt) 2021-04-15
EP3173071A1 (en) 2017-05-31
PL3173071T3 (pl) 2021-08-16
EP3173071B2 (en) 2025-12-24
DK3173071T3 (da) 2021-06-28
FI3173071T4 (fi) 2026-02-06
CY1124893T1 (el) 2023-01-05
SI3173071T1 (sl) 2021-11-30
RS62057B1 (sr) 2021-07-30
HRP20210986T1 (hr) 2021-09-17
ES2873376T3 (es) 2021-11-03
LT3173071T (lt) 2021-07-12

Similar Documents

Publication Publication Date Title
IL257279A (en) Anti-Epner 1 formulation is stable
GB2551985B (en) Novel formulation
GB201513010D0 (en) Novel formulation
GB201407934D0 (en) Formulation
PL3364945T3 (pl) Stały preparat
GB201514758D0 (en) Formulation
PT3173071T (pt) Formulação de maropitant
GB201407384D0 (en) Formulation
IL248835B (en) A preparation of ciritinib
GB201608356D0 (en) Formulation
GB201511301D0 (en) Formulation
IL251362A0 (en) formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201514014D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201609925D0 (en) Formulation
GB201602048D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation